

Table of contents :

1. Introduction	1
2. Aim of the work and methods of research	4
3. Background information on DR-TB and global efforts to limit the problem	5
4. Epidemiology of DR-TB	
• Definitions	18
• MDR-TB incidence, prevalence and mortality	20
• Factors favoring development of resistance	32
• Clinical significance of primary and acquired resistance	37
• Identification of drug resistance mutations in TB	40
• Development of diagnostic tests for drug resistance	42
• Geographical distribution and surveillance of mutations	44
• Drug discovery	46
• Data base for drug resistant mutations	47
• Epidemiologic importance of available treatments	50
5. Mechanisms of drug resistance	
• Overview of mechanism of drug resistance	53
• Molecular mechanisms of resistance to different drug groups	57
▪ Resistance to INH	58

▪ Resistance to RIF	63
▪ Resistance to EMB	66
▪ Resistance to PZA	68
▪ Resistance to FQ	70
▪ Resistance to Streptomycin and other protein synthesis inhibitors	71
▪ Resistance to other drugs	73

6. Diagnosis of drug resistant TB

• Conventional and Rapid culture methods	76
• Early detection by molecular mechanisms	83
▪ Sequencing	83
▪ Probe-based hybridization methods	83
▪ PCR-restriction fragment length polymorphism (PCRRFLP)	84
▪ Single stranded conformation polymorphism analysis (SSCP)	84
▪ Heteroduplex analysis (HA)	85
▪ Molecular beacons	86
▪ Amplification refractory mutation system (ARMS)-PCR	87

7. Treatment of MDR- TB

• Factors affecting response to treatment	89
• Current available drugs and regimens for treatment	91
• Monitoring response to treatment and precautions	95
• Management of MDR- TB treatment failure patients	97
• Role of surgery	100
• New drugs and future possibilities	104
• Suspending treatment for MDR-XDR -TB patients	121
• Supportive care for patients who failed all treatment possibilities	124

8. Nanotechnology as a future therapy for MDR-TB

• Nanotechnology in diagnosis of tuberculosis	126
• Nanotechnology in treatment of tuberculosis	127
• Nanotechnology in vaccination for tuberculosis	131

9. Control of MDR/XDR - TB

• Framework for optimal control	133
• Case finding strategies	143
• Effective treatment of detected patients	161
• Effective contact management	164

10.MDR / XDR - TB as a global problem

• Magnitude of resistance by region	171
• Global burden of MDR	192
• Supra National Laboratory Network (SRLN)	199
• Drug resistance patterns	202
• Drug resistance amplification	204
11. MDR / XDR -TB as a local problem in Egypt	206
12. Summary	223
13. References	235